<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Analysis of aberrant hypermethylation in stool DNA might provide a novel strategy for noninvasive detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: To explore the feasibility of detecting hypermethylation in <z:hpo ids='HP_0001258'>Spastic paraplegia</z:hpo>-20 promoter as a stool-based DNA marker for detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We collected 96 tissue and stool samples from patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and 30 stool samples healthy individuals </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Hypermethylated <z:hpo ids='HP_0001258'>Spastic paraplegia</z:hpo>-20 occurs in 85.4% (82/96) of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in the tissue samples </plain></SENT>
<SENT sid="4" pm="."><plain>In the stool samples, the results indicate 80.2% (77/96) sensitivity and 100% (30/30) specificity of the test for detecting <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> by using the stool samples as a noninvasive method </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: The study reveals that hypermethylation in <z:hpo ids='HP_0001258'>Spastic paraplegia</z:hpo>-20 promoter is a highly specific and sensitive biomarker for screening <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in stool samples as a noninvasive method </plain></SENT>
</text></document>